---
schema_version: "secwatch.filing_event.v1"
accession: "0000886163-23-000089"
form_type: "8-K/A"
ticker: "LGND"
cik: "0000886163"
company_name: "LIGAND PHARMACEUTICALS INC"
filed_at: "2023-11-13T23:59:59+00:00"
generated_at: "2026-06-08T05:57:00.469809+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Ligand Q3 adj EPS $1.02 beats, raises 2023 guidance; restates prior net loss per share to ($0.59)

## Summary
- Q3 total revenue $32.9M (down from $59.2M YoY, no COVID-19 sales); adjusted EPS $1.02 vs $0.60 YoY.
- Raised 2023 revenue guidance to $126-129M (from $124-126M) and adjusted EPS to $5.25-5.40 (from $5.10-5.25).
- 8-K/A correction: $3.2M derivative asset from Pelican divestiture changed sale from ($1.1M) loss to $2.1M gain; net loss per share improved to ($0.59) from ($0.74).
- Invested >$75M in Q3/Q4 in Tolerance, Ovid, Novan, Primrose; acquired 13% royalty interest in soticlestat (up to $86M milestones).
- Cash and short-term investments $190.5M at Sep 30, 2023; new $75M revolving credit facility with Citibank.

## SEC filing metadata
- accession: 0000886163-23-000089
- form_type: 8-K/A
- ticker: LGND
- cik: 0000886163
- company_name: LIGAND PHARMACEUTICALS INC
- filed_at: 2023-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/886163/000088616323000089/0000886163-23-000089-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/886163/000088616323000089/lgnd-20231109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000886163-23-000089
- JSON: https://secwatch.observer/filing/0000886163-23-000089.json
- Plain text: https://secwatch.observer/filing/0000886163-23-000089.txt

## Key facts
- Earnings Releases
  LIGAND PHARMACEUTICALS INC reported three and nine months ended September 30, 2023 results: revenue $32.9 million, net income $10.3 million net loss, EPS $0.59 per share loss. Guidance raised.
  - Period: three and nine months ended September 30, 2023
  - Revenue: $32.9 million
  - Net income: $10.3 million net loss
  - EPS: $0.59 per share loss
  - Guidance: raised
  - Result: reported results
  source text: at our upcoming Investor and Analyst Day scheduled for December 12th in New York City.” Third Quarter 2023 Financial Results Total revenues for the third quarter of 2023 were $32.9 million. Revenues for the same period in 2022 excluding sales related to COVID-19 were $26.9 million. Total revenues for the third quarter of 2022 including COVID-19 related sales were
  evidence_url: https://www.sec.gov/Archives/edgar/data/886163/000088616323000089/0000886163-23-000089-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.